The global Radiotherapy Induced Oral Mucositis Treatment Market is expected to generate a market value of US$ 3 billion in 2023 and a market value of US$ 4.89 billion by 2033, with a CAGR of 5% from 2023 to 2033. From 2018 to 2022, the market for Radiotherapy Induced Oral Mucositis Treatment grew at a CAGR of 3.5%.
Radiotherapy-induced oral mucositis is a painful and debilitating side effect of radiotherapy treatment for cancer patients. It is estimated that approximately 40% to 100% of patients who undergo radiotherapy for head and neck cancer will develop Radiotherapy Induced Oral Mucositis. This condition can significantly impact patients’ quality of life, causing pain, difficulty eating, and increased risk of infection. However, there are several treatments available for Radiotherapy Induced Oral Mucositis, including drugs, mouthwashes, gels, and other therapies.
The global Radiotherapy Induced Oral Mucositis Treatment Market is expected to grow significantly from 2018 to 2022, with a continued upward trajectory in demand from 2023 to 2033. One of the key drivers of the Radiotherapy Induced Oral Mucositis treatment market is the increasing incidence of cancer.
For more insights into the market, request a sample of this report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16820
According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018. As the incidence of cancer continues to rise, the number of patients undergoing radiotherapy is also increasing, leading to a higher prevalence of Radiotherapy Induced Oral Mucositis.
Another factor driving the growth of the Radiotherapy Induced Oral Mucositis treatment market is the increasing awareness of Radiotherapy Induced Oral Mucositis among healthcare providers and patients. Radiotherapy Induced Oral Mucositis is a well-known side effect of radiotherapy, and healthcare providers are increasingly taking steps to prevent and manage this condition in their patients. Additionally, patients are becoming more informed about Radiotherapy Induced Oral Mucositis and are seeking out effective treatments to manage their symptoms.
According to a new market research report published by Future Market insights, the global Radiotherapy Induced Oral Mucositis Treatment market is expected to grow at a CAGR of 5% from 2023 to 2033, reaching a market size of USD 4.89 Billion by 2033.
Key Takeaways from the Market Study
- From 2018 to 2022, the Radiotherapy Induced Oral Mucositis Treatment market grew at a CAGR of 3.5%.
- The global Radiotherapy Induced Oral Mucositis Treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
- As of 2033, the Radiotherapy Induced Oral Mucositis Treatment Market is expected to reach US$ 4.89 Billion.
- According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Radiotherapy Induced Oral Mucositis Treatment market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-16820
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Radiation-induced Oral Mucositis Management.” says an FMI analyst
Market Competition
Key players in the market include companies such as Izun Pharmaceuticals, Soleva Pharma, Aurora Bioscience, INNOVATION Pharma, Camurus AB, Monopar Therapeutics, Prothex Inc., Access Pharmaceutical Inc., Swedish Orphan Biovitrum, NeoMedLight along with healthcare providers and technology companies among other global players.
- Galera Therapeutics announced that the FDA has accepted and granted priority review to a new drug application for avasopasem manganese (GC4419) for patients suffering from radiotherapy-induced severe oral mucositis caused by head and neck cancer. The Prescription Drug User Fee Act date for avasopasem has been set for August 9, 2023. If approved, avasopasem will be the first drug approved by the FDA for reducing radiotherapy-induced severe oral mucositis in patients with head and neck cancer.
Last few days to get reports at discounted prices, the offer expires soon!
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-16820
Key Segments Profiled in the Radiotherapy Induced Oral Mucositis Treatment Industry Survey
Drug Class:
- Antibiotics
- Antifungal
- Anti-Inflammatory
- Anti-Neoplastic
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
End User:
- Hospitals
- Oncology Centres
- Research Institutes
- Dental Clinics
Have a Look at Related Research Reports in the Healthcare Domain:
- https://bpa-mastery.mn.co/posts/34431327
- https://chineseintheus.mn.co/posts/nurse-call-systems-market-is-expected-to-reach-a-valuation-of-us-455-billion-by-2033-fmi
- https://diecast64.mn.co/posts/34431071
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs